LBA-1 RATIONALE-306: Randomized, global, placebo-controlled, double-blind phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC)

Hyun-Woo Yoon, Ken Kato, Eric Raymond, Richard Hubner, Y. Shu, Yunfeng Pan, Yu Lei Jiang, J. Zhang, Sunmin Park, Takashi Kojima, Chia-Hung Lin, E. Gotovkin, Lucjan Wyrwicz, Ryu Ishihara, L. Li, Ariana Tao, Jingwen Shi, L. Wang, Jiangtao Xu